Amgen’s US Amjevita Sales Slow While Other Growth Drivers Deliver

 
• By Jessica Merrill

Sales of the Humira biosimilar increased double digits globally year over year, but declined 63% in the US versus Q1 due to inventory stockpiling.

slow start
Amjevita sales in the US got off to a slow start • Source: Shutterstock

The US launch of Amgen, Inc.’s Amjevita – the first biosimilar of AbbVie Inc.’s blockbuster Humira (adalimumab) – is off to a slow start. The company reported second quarter sales on 3 August, with US sales of Amjevita declining versus the first quarter, which the company attributed to inventory stocking associated with the launch in January.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business